Tern Plc issues 78.2m shares following Open Offer

TERN

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things technology businesses, has announced the results of its Open Offer to Qualifying Shareholders which was announced on 13 February 2026 and closed for acceptances, in accordance with its terms, on 2 March 2026.

The Company announces that valid acceptances have been received from Qualifying Shareholders for a total of 78,163,662 new Ordinary Shares under the Open Offer, representing a take-up of approximately 81% of the 96,101,957 Open Offer Shares available.

As a result, and subject to Admission becoming effective, 78,163,662 Open Offer Shares will be issued in connection with the Open Offer, raising approximately £312,654 (before expenses and including the loan conversion*) for the Company at the Issue Price of 0.40 pence per Open Offer Share.

Further announcements are expected to be made in due course in relation to the application of the net proceeds of the Open Offer.

Capitalised terms used but not otherwise defined in this announcement bear the meanings ascribed to them in the circular posted to shareholders on 13 February 2026.

Director and PDMR participation in the Open Offer

The following Director and persons discharging managerial responsibilities (“PDMRs“) of the Company have participated in the Open Offer, as follows:

DirectorNumber of Existing Ordinary SharesNumber of Open Offer Shares subscribed forNumber of Ordinary Shares held on Admission% of the Enlarged Share Capital on Admission
Iain Ross1,613,332230,4761,843,8080.24%
PDMRNumber of Existing Ordinary SharesNumber of Open Offer Shares subscribed for*Number of Ordinary Shares held on Admission% of the Enlarged Share Capital on Admission
Albert Sisto13,328,6817,797,41521,126,0962.81%

*As described in Tern Plc’s Circular to Shareholders posted on 13 February 2026, an existing loan of US$42,000 from a vehicle controlled by Albert Sisto has had its value used as a contribution towards his subscription in the Open Offer, rather than require it to be repaid.

The notifications below, made in accordance with the requirements of the EU Market Abuse Regulation (2014/596/EU) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 and as modified by or under the European Union (Withdrawal) Act 2018 or other domestic law, provides further detail.

Admission and dealings

The Open Offer Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with each other and with the Existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of Admission. Application has been made to the London Stock Exchange for the Open Offer Shares to be admitted to trading on AIM. Dealings in the Open Offer Shares and Admission are expected to take place on or around 8.00 a.m. on 4 March 2026.

Total voting rights

In accordance with the Financial Conduct Authority’s Disclosure, Guidance and Transparency Rules, the Company confirms that following Admission, the Company’s enlarged issued ordinary share capital will comprise 750,877,367 Ordinary Shares. The Company does not hold any shares in Treasury.  Therefore, from Admission, the total number of voting rights in the Company will be 750,877,367 and this figure may be used by shareholders in the Company as the denominator for the calculations to determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure Guidance and Transparency Rules.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Tern invests £78,000 in Device Authority through 8% convertible loan notes

Tern Plc has committed approximately £78,000 to new convertible loan notes issued by Device Authority, which carry 8% annual...

Search